SevenPointOne is an innovative AI healthcare company setting a new standard for brain health management through voice-based AI technology. Its flagship solution, “AlzWIN,” is AI-based software that quickly and accurately screens for the risk of cognitive decline by analyzing just one minute of a subject’s voice data. By digitizing the language fluency assessment method, it enables remote testing without spatial or temporal constraints. AlzWIN has secured global-level technological reliability and validity by completing registration with the U.S. Food and Drug Administration (FDA). Subsequently, it successfully completed confirmatory clinical trials for medical device approval from the Ministry of Food and Drug Safety (MFDS) in South Korea, officially demonstrating its academic and clinical validity. It is currently being widely adopted not only in medical infrastructure, such as senior care facilities, local public health centers, and hospitals and clinics, but also in insurance companies’ customer health management and product-linked services. In this era of super-aging, AlzWin is leading the way in everyday cognitive care by dramatically improving access to early diagnosis.